JP5257901B2 - ローソニア・イントラセルラリス感染に対する幼若動物のワクチン接種 - Google Patents
ローソニア・イントラセルラリス感染に対する幼若動物のワクチン接種 Download PDFInfo
- Publication number
- JP5257901B2 JP5257901B2 JP2009512301A JP2009512301A JP5257901B2 JP 5257901 B2 JP5257901 B2 JP 5257901B2 JP 2009512301 A JP2009512301 A JP 2009512301A JP 2009512301 A JP2009512301 A JP 2009512301A JP 5257901 B2 JP5257901 B2 JP 5257901B2
- Authority
- JP
- Japan
- Prior art keywords
- intracellularis
- mammal
- day
- days
- vaccinated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001148567 Lawsonia intracellularis Species 0.000 title claims description 156
- 238000002255 vaccination Methods 0.000 title claims description 47
- 208000015181 infectious disease Diseases 0.000 title claims description 32
- 230000000366 juvenile effect Effects 0.000 title claims description 16
- 229960005486 vaccine Drugs 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 50
- 241000124008 Mammalia Species 0.000 claims description 30
- 230000008774 maternal effect Effects 0.000 claims description 18
- 230000002238 attenuated effect Effects 0.000 claims description 13
- 210000002966 serum Anatomy 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000035622 drinking Effects 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 4
- 241000288906 Primates Species 0.000 claims description 4
- 241000283086 Equidae Species 0.000 claims description 3
- -1 nti Species 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 241000282412 Homo Species 0.000 claims 7
- 241001465754 Metazoa Species 0.000 description 95
- 241000282887 Suidae Species 0.000 description 68
- 239000000427 antigen Substances 0.000 description 40
- 102000036639 antigens Human genes 0.000 description 40
- 108091007433 antigens Proteins 0.000 description 40
- 241000282898 Sus scrofa Species 0.000 description 36
- 238000002474 experimental method Methods 0.000 description 33
- 230000002163 immunogen Effects 0.000 description 23
- 235000021277 colostrum Nutrition 0.000 description 21
- 210000003022 colostrum Anatomy 0.000 description 21
- 235000013336 milk Nutrition 0.000 description 19
- 239000008267 milk Substances 0.000 description 19
- 210000004080 milk Anatomy 0.000 description 19
- 239000000203 mixture Substances 0.000 description 18
- 230000003902 lesion Effects 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 15
- 239000002671 adjuvant Substances 0.000 description 14
- 230000028993 immune response Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- 210000001072 colon Anatomy 0.000 description 12
- 208000009326 ileitis Diseases 0.000 description 12
- 235000021052 average daily weight gain Nutrition 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 210000003405 ileum Anatomy 0.000 description 10
- 241001469654 Lawsonia <weevil> Species 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000002550 fecal effect Effects 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000012384 transportation and delivery Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 5
- 210000004534 cecum Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000003903 intestinal lesions Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000006651 lactation Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical class CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000000521 hyperimmunizing effect Effects 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000032696 parturition Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000034423 Delivery Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 1
- RFIMISVNSAUMBU-UHFFFAOYSA-N 2-(hydroxymethyl)-2-(prop-2-enoxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC=C RFIMISVNSAUMBU-UHFFFAOYSA-N 0.000 description 1
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 1
- UMHYVXGZRGOICM-AUYXYSRISA-N 2-[(z)-octadec-9-enoyl]oxypropyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC\C=C/CCCCCCCC UMHYVXGZRGOICM-AUYXYSRISA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QWVRTSZDKPRPDF-UHFFFAOYSA-N 5-(piperidin-1-ylmethyl)-3-pyridin-3-yl-5,6-dihydro-2h-1,2,4-oxadiazine Chemical compound C1CCCCN1CC(N=1)CONC=1C1=CC=CN=C1 QWVRTSZDKPRPDF-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000010755 BS 2869 Class G Substances 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 206010047897 Weight gain poor Diseases 0.000 description 1
- NKVLDFAVEWLOCX-GUSKIFEASA-N [(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxy-6-methyloxan-2-yl] (4ar,5r,6as,6br,9s,10s,12ar)-10-[(2r,3r,4s, Chemical compound O([C@H]1[C@H](O)CO[C@H]([C@@H]1O)O[C@H]1[C@H](C)O[C@H]([C@@H]([C@@H]1O)O)O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@H]1OC(=O)[C@]12CCC(C)(C)CC1C1=CCC3[C@@]([C@@]1(C[C@H]2O)C)(C)CCC1[C@]3(C)CC[C@@H]([C@@]1(C)C=O)O[C@@H]1O[C@@H]([C@H]([C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)[C@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O)C(=O)NCCCCCCCCCCCC)[C@@H]1OC[C@](O)(CO)[C@H]1O NKVLDFAVEWLOCX-GUSKIFEASA-N 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229940086737 allyl sucrose Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 235000021051 daily weight gain Nutrition 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 244000309465 heifer Species 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000001983 lactogenic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- AFFLGGQVNFXPEV-UHFFFAOYSA-N n-decene Natural products CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940010310 propylene glycol dioleate Drugs 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012770 revaccination Methods 0.000 description 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000013026 undiluted sample Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80320706P | 2006-05-25 | 2006-05-25 | |
| US60/803,207 | 2006-05-25 | ||
| US11/750,458 | 2007-05-18 | ||
| US11/750,458 US8470336B2 (en) | 2006-05-25 | 2007-05-18 | Vaccination of young animals against Lawsonia intracellularis infections |
| PCT/US2007/069646 WO2007140244A2 (en) | 2006-05-25 | 2007-05-24 | Vaccination of young animals against lawsonia intracellularis infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009538344A JP2009538344A (ja) | 2009-11-05 |
| JP2009538344A5 JP2009538344A5 (enExample) | 2010-07-15 |
| JP5257901B2 true JP5257901B2 (ja) | 2013-08-07 |
Family
ID=38779345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009512301A Active JP5257901B2 (ja) | 2006-05-25 | 2007-05-24 | ローソニア・イントラセルラリス感染に対する幼若動物のワクチン接種 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8470336B2 (enExample) |
| EP (1) | EP2029166A4 (enExample) |
| JP (1) | JP5257901B2 (enExample) |
| KR (2) | KR20090018838A (enExample) |
| CN (1) | CN103394080A (enExample) |
| AU (1) | AU2007267574B2 (enExample) |
| CA (1) | CA2652049C (enExample) |
| MX (1) | MX2008014882A (enExample) |
| WO (1) | WO2007140244A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8834891B2 (en) | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
| US8398994B2 (en) * | 2005-07-15 | 2013-03-19 | Boehringer Ingelheim Vetmedica, Inc. | Lawsonia vaccine and methods of use thereof |
| US8470336B2 (en) | 2006-05-25 | 2013-06-25 | Boehringer Ingelheim Vetmedica, Inc. | Vaccination of young animals against Lawsonia intracellularis infections |
| US20080241190A1 (en) * | 2006-11-13 | 2008-10-02 | Boehringer Ingelheim Vetmedica, Inc. | Vaccination of horses against lawsonia intracellularis |
| EP2200643B1 (en) * | 2007-09-17 | 2013-09-04 | Boehringer Ingelheim Vetmedica, Inc. | A live lawsonia intracellularis vaccine administered in combination with an antibiotic for use in the treatment of lawsonia intracellularis infections in pigs |
| TWI551295B (zh) | 2008-04-18 | 2016-10-01 | 英特威特國際股份有限公司 | 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗 |
| ES2534556T3 (es) * | 2008-07-22 | 2015-04-24 | Intervet International Bv | Bacteria Lawsonia intracellularis de un nuevo serotipo, vacuna basada en esa bacteria, anticuerpos adecuados para diagnosticar el nuevo serotipo de Lawsonia intracellularis e hibridomas para producir dichos anticuerpos |
| US10265392B2 (en) * | 2015-02-04 | 2019-04-23 | Intervet Inc. | Vaccine for use against subclinical Lawsonia infection in a pig |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3479430A (en) | 1967-08-24 | 1969-11-18 | Diamond Lab Inc | Indirect passive immunization against transmissible gastroenteritis virus in nursing piglets at birth by active immunization of sows prior to farrowing with transmissible gastroenteritis vaccine and method of producing the same |
| US3907987A (en) | 1972-05-25 | 1975-09-23 | Canadian Patents Dev | Enteric disease vaccine |
| US4132597A (en) | 1976-06-09 | 1979-01-02 | Ab Medipharm | Method for cultivation of bacteria |
| US4237218A (en) | 1979-02-09 | 1980-12-02 | Bio-Rad Laboratories, Inc. | Micro-carrier cell culture |
| NL8102786A (nl) * | 1981-06-10 | 1983-01-03 | Duphar Int Res | Werkwijze voor het immuniseren van varkens tegen de ziekte van aujeszky. |
| JPS5991879A (ja) | 1982-11-16 | 1984-05-26 | Hideaki Yamada | シユ−ドモナス属細菌の培養法 |
| DK594084A (da) | 1984-12-12 | 1986-06-13 | Novo Industri As | Fremgangsmaade til stabilisering af extra-chromosomale elementer i bakterier under dyrkning |
| JPH0644865B2 (ja) | 1985-10-29 | 1994-06-15 | 三菱瓦斯化学株式会社 | カンピロバクタ−属細菌の培養方法 |
| JPS62198627A (ja) * | 1986-02-26 | 1987-09-02 | Biseibutsu Kagaku Kenkyusho:Kk | オ−エスキ−病可溶化抗原ワクチン |
| US5338670A (en) | 1986-07-28 | 1994-08-16 | The United States Of America As Represented By The Department Of Health And Human Services | Production of bordetella pertussis toxin with a low concentration of iron |
| IT1227657B (it) | 1988-12-01 | 1991-04-23 | Mini Ricerca Scient Tecnolog | Antibiotici ab-021 e processo per la loro produzione |
| JPH0822221B2 (ja) | 1988-12-28 | 1996-03-06 | 日東化学工業株式会社 | シュードモナス属細菌の培養法 |
| JPH02308754A (ja) | 1989-05-24 | 1990-12-21 | Yakult Honsha Co Ltd | 乳発酵食品の製造法 |
| US5296221A (en) | 1990-01-31 | 1994-03-22 | Sani-Ei Sucrochemical Co., Ltd. | Lactobacillus johnsonii ferm bp-2680 lactic acid bacteria preparations using the same and a process of manufacturing the preparations |
| US5192679A (en) | 1990-05-03 | 1993-03-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Growing ehrlichia species in a continuous cell line |
| EP0555366B1 (en) | 1990-11-01 | 2000-06-28 | Iowa State University Research Foundation, Inc. | Bacterial attenuation method and vaccine |
| DE4208785A1 (de) | 1992-03-19 | 1993-09-23 | Degussa | Verfahren zum auffinden von insertionselementen (is-elemente) oder transposonen |
| DK0839050T3 (da) | 1992-09-28 | 2004-10-25 | Wyeth Corp | Fremgangsmåde til at forstærke celleformidlede immunreaktioner |
| US5610059A (en) | 1992-11-09 | 1997-03-11 | University Of Arizona | Etiological agent for porcine enteritis |
| US5885823A (en) * | 1995-06-05 | 1999-03-23 | Nobl Laboratories, Inc. | Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents |
| US5714375A (en) | 1995-06-05 | 1998-02-03 | Nobl Laboratories, Inc. | Ileal symbiont intracellularis propagation in suspended host cells |
| JP2000502054A (ja) | 1995-11-30 | 2000-02-22 | アグリカルチャー ビクトリア サービシーズ ピーティーワイ．エルティーディー． | 治療用および診断用の組成物 |
| US7052697B1 (en) | 1999-05-13 | 2006-05-30 | Agriculture Victoria Services Pty Ltd | Lawsonia derived gene and related OmpH polypeptides, peptides and proteins and their uses |
| US20030157120A1 (en) | 1999-05-13 | 2003-08-21 | Michael Panaccio | Lawsonia derived gene and related flge polypeptides, peptides and proteins and their uses |
| US6414036B1 (en) | 1999-09-01 | 2002-07-02 | Van Beek Global/Ninkov Llc | Composition for treatment of infections of humans and animals |
| US6605696B1 (en) | 1999-10-22 | 2003-08-12 | Pfizer, Inc. | Lawsonia intracellularis proteins, and related methods and materials |
| EP1094070A3 (en) * | 1999-10-22 | 2002-01-09 | Pfizer Products Inc. | Lawsonia intracellularis proteins, and related methods and materials |
| AU784344B2 (en) * | 2000-01-28 | 2006-03-16 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Compositions and method for preventing reactogenicity associated with administration of immunogenic live rotavirus compositions |
| CN1443076A (zh) | 2000-05-24 | 2003-09-17 | 梅瑞尔公司 | 猪生殖和呼吸综合症病毒(prrsv)重组禽痘病毒疫苗 |
| MY128159A (en) | 2000-06-30 | 2007-01-31 | Wyeth Corp | Methods and composition for oral vaccination |
| JP2004529854A (ja) | 2000-09-29 | 2004-09-30 | アリゾナ・ボード・オブ・リージエンツ・オン・ビハーフ・オブ・ザ・ユニバーシテイー・オブ・アリゾナ | 増殖性回腸炎のための改善されたワクチン及びその作製と使用の方法 |
| US20020103261A1 (en) | 2000-10-06 | 2002-08-01 | Dusan Ninkov | Compositions for injection or intravenous administration for the treatment of internal infection or inflammation in humans and animals |
| DE60144201D1 (de) | 2000-12-20 | 2011-04-21 | Intervet Int Bv | Lawsonia intracellularis Impfstoff |
| US20030087421A1 (en) | 2001-07-11 | 2003-05-08 | Gebhart Connie J | Lawsonia intracellularis |
| EP1570045A4 (en) | 2002-10-04 | 2007-09-05 | Univ Minnesota | NUCLEIC ACID AND POLYPEPTIDE SEQUENCES FROM LAWSONIA INTRACELLULARIS AND METHOD OF USE |
| UA87665C2 (ru) | 2003-07-25 | 2009-08-10 | Берингер Ингельхайм Ветмедика, Инк. | Авирулентный изолят lawsonia intracellularis европейского происхождения, вакцина для иммунизации животных, применение заявленного авирулентного изолята как вакцины, способ получения вакцины, способ культивирования lawsonia intracellularis, способ диагностики пролиферативной энтеропатии свиней и способ получения антисыворотки к lawsonia intracellularis |
| CN1849334A (zh) | 2003-09-12 | 2006-10-18 | 阿克佐诺贝尔公司 | 胞内劳森氏菌亚单位疫苗 |
| BRPI0507017A (pt) | 2004-01-22 | 2007-06-05 | Intervet Int Bv | ácido nucleico que codifica uma proteìna de lawsonia intracellularis, fragmento de dna, molécula de dna recombinante, carreador recombinante vivo, célula hospedeira, proteìna de lawsonia intracellularis, uso da mesma, vacina para combater as infecções por lawsonia intracellularis, método para preparação da mesma, e, teste de diagnóstico |
| US7550270B2 (en) | 2004-08-13 | 2009-06-23 | Boehringer Ingelheim Vetmedica, Inc. | Ileitis diagnostic assay |
| US20070212373A1 (en) | 2004-12-08 | 2007-09-13 | Akzo Nobel N.V. | Lawsonia Intracellularis 26 Kd Subunit Vaccine |
| US8834891B2 (en) | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
| US20090215698A1 (en) | 2005-04-18 | 2009-08-27 | Boehringer Ingelheim Vetmedica, Inc. | Lawsonia protein useful as a component in subunit vaccine and methods of making and using thereof |
| JP2009509496A (ja) | 2005-04-28 | 2009-03-12 | ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド | ローソニアイントラセルラリスの免疫学的タンパク |
| US8398994B2 (en) * | 2005-07-15 | 2013-03-19 | Boehringer Ingelheim Vetmedica, Inc. | Lawsonia vaccine and methods of use thereof |
| EP3320919B1 (en) | 2005-12-29 | 2020-05-27 | Boehringer Ingelheim Animal Health USA Inc. | Multivalent pcv2 immunogenic compositions and methods of producing such compositions |
| US8470336B2 (en) | 2006-05-25 | 2013-06-25 | Boehringer Ingelheim Vetmedica, Inc. | Vaccination of young animals against Lawsonia intracellularis infections |
| US20080241190A1 (en) | 2006-11-13 | 2008-10-02 | Boehringer Ingelheim Vetmedica, Inc. | Vaccination of horses against lawsonia intracellularis |
| EP2200643B1 (en) | 2007-09-17 | 2013-09-04 | Boehringer Ingelheim Vetmedica, Inc. | A live lawsonia intracellularis vaccine administered in combination with an antibiotic for use in the treatment of lawsonia intracellularis infections in pigs |
| US8142760B2 (en) | 2008-09-05 | 2012-03-27 | Nathan Len Winkelman | Vaccination for Lawsonia intracellularis |
-
2007
- 2007-05-18 US US11/750,458 patent/US8470336B2/en active Active
- 2007-05-24 WO PCT/US2007/069646 patent/WO2007140244A2/en not_active Ceased
- 2007-05-24 KR KR1020087031302A patent/KR20090018838A/ko not_active Ceased
- 2007-05-24 AU AU2007267574A patent/AU2007267574B2/en active Active
- 2007-05-24 KR KR1020147019352A patent/KR20140093757A/ko not_active Withdrawn
- 2007-05-24 MX MX2008014882A patent/MX2008014882A/es active IP Right Grant
- 2007-05-24 CN CN2013100839479A patent/CN103394080A/zh active Pending
- 2007-05-24 JP JP2009512301A patent/JP5257901B2/ja active Active
- 2007-05-24 CA CA2652049A patent/CA2652049C/en active Active
- 2007-05-24 EP EP07797730A patent/EP2029166A4/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN103394080A (zh) | 2013-11-20 |
| US8470336B2 (en) | 2013-06-25 |
| WO2007140244A2 (en) | 2007-12-06 |
| CA2652049A1 (en) | 2007-12-06 |
| CA2652049C (en) | 2015-12-22 |
| AU2007267574B2 (en) | 2013-02-21 |
| US20080063648A1 (en) | 2008-03-13 |
| JP2009538344A (ja) | 2009-11-05 |
| KR20140093757A (ko) | 2014-07-28 |
| AU2007267574A1 (en) | 2007-12-06 |
| WO2007140244A3 (en) | 2008-09-12 |
| EP2029166A2 (en) | 2009-03-04 |
| EP2029166A4 (en) | 2009-08-26 |
| MX2008014882A (es) | 2008-12-05 |
| KR20090018838A (ko) | 2009-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101175509B (zh) | 含有胞内劳森菌的免疫原性组合物 | |
| JP5257901B2 (ja) | ローソニア・イントラセルラリス感染に対する幼若動物のワクチン接種 | |
| US20130164332A1 (en) | Lawsonia vaccine and methods of use thereof | |
| TW200835515A (en) | Treatment of pigs with PCV2 antigen | |
| CN111757752B (zh) | 用于减少动物中的粪臭素和/或吲哚的方法 | |
| US20080241190A1 (en) | Vaccination of horses against lawsonia intracellularis | |
| JP2021035982A (ja) | 豚における無症候性ローソニア感染症に対する使用のためのワクチン | |
| CN101454020A (zh) | 对年幼动物免疫接种以抵抗胞内劳森菌感染 | |
| JP5723772B2 (ja) | 新規血清型のローソニア・イントラセルラリス細菌、その細菌に基づくワクチン、該新規ローソニア・イントラセルラリス血清型の特定に適した抗体および該抗体を製造するためのハイブリドーマ | |
| BRPI0712164A2 (pt) | vacinação de animais jovens infecções por lawsonia intracellularis | |
| TW200829268A (en) | Vaccination of horses against lawsonia intracellularis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100524 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100524 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120730 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121026 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121102 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130130 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130401 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130416 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160502 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5257901 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |